|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:gastrointestinal_stromal_tumor
gptkb:chronic_myeloid_leukemia
2001
|
|
gptkbp:ATCCode
|
L01EA01
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:blackBoxWarning
|
no
|
|
gptkbp:CASNumber
|
152459-95-5
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:discoveredIn
|
1996
|
|
gptkbp:drugClass
|
gptkb:protease_inhibitor
gptkb:antineoplastic_agent
inhibits BCR-ABL tyrosine kinase
inhibits PDGFR
inhibits c-Kit
|
|
gptkbp:eliminatedIn
|
renal
fecal
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
gptkbp:hasInChIKey
|
gptkb:KHGXJUYNMMXHFG-UHFFFAOYSA-N
|
|
gptkbp:hasLogP
|
4.53
|
|
gptkbp:hasMolecularFormula
|
C29H31N7O
|
|
gptkbp:hasPatentExpiry
|
2015
|
|
gptkbp:hasSMILES
|
CC1=CC=CC=C1NC(=O)C2=CC=CC=C2C3=NC=CC(=N3)N4CCN(CC4)C5=NC=CC=C5
|
|
gptkbp:hasUNII
|
8C8O2UF0ZV
|
|
gptkbp:KEGGID
|
D08177
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:meltingPoint
|
214-215°C
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
493.6 g/mol
|
|
gptkbp:name
|
gptkb:Imatinib
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEBI:45783
gptkb:DB00619
5291
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
edema
fatigue
rash
muscle cramps
|
|
gptkbp:structureType
|
gptkb:small_molecule
|
|
gptkbp:synonym
|
gptkb:Gleevec
gptkb:Glivec
gptkb:STI-571
|
|
gptkbp:target
|
gptkb:BCR-ABL
gptkb:PDGFR
gptkb:c-Kit
|
|
gptkbp:bfsParent
|
gptkb:LY294002
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL958
|